Revolution Medicines Joins Rank Of Stocks With RS Ratings Over 90

Revolution Medicines (RVMD) had its Relative Strength (RS) Rating upgraded from 87 to 93 Thursday.

X



IBD’s unique RS Rating identifies technical performance by showing how a stock’s price action over the last 52 weeks measures up against that of the other stocks in our database.

Decades of market research shows that the best-performing stocks often have an RS Rating north of 80 at the beginning of a new price run.

How To Use Stock Charts To Stay Profitable And Protected

While Revolution Medicines is not near a proper buy point right now, see if it is able to form and break out of a proper chart pattern.

Revolution Medicines reported 0% EPS growth in its most recent report. Revenue rose -95%. The company is expected to report its latest earnings and sales numbers on or around May 6.

The company holds the No. 205 rank among its peers in the Medical-Biomed/Biotech industry group. Neurocrine Biosciences (NBIX), Alpine Immune Sciences (ALPN) and Catalyst Pharmaceuticals (CPRX) are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Ready To Grow Your Investing Skills? Join An IBD Meetup Group!